Time-dependent reduction and potentiation of growth hormone (GH) responsiveness to GH-releasing factor induced by exogenous GH: role for somatostatin
- PMID: 1347739
- DOI: 10.1210/endo.130.4.1347739
Time-dependent reduction and potentiation of growth hormone (GH) responsiveness to GH-releasing factor induced by exogenous GH: role for somatostatin
Abstract
Exogenous GH is known to exert a negative feedback effect on its own responsiveness to GH-releasing factor (GRF); however, the mechanism is not known. In the present study we examined the time course of effects of a single sc administration of recombinant human (rh) GH on GH responsiveness to GRF and investigated the possible involvement of somatostatin (SRIF) in this response. Free-moving adult male rats were administered 200 micrograms rhGH, sc, at 0800 h and subsequently challenged with 1 microgram GRF-(1-29)NH2, iv, at times of spontaneous peaks (1100 and 1500 h) and troughs (1300 h) in GH secretion during a 6-h (1000-1600 h) sampling period. H2O-injected control rats exhibited the typical cyclic responsiveness to GRF stimulation, with GRF-induced GH release significantly greater during peak compared to trough periods of the GH rhythm. Pretreatment with rhGH 3 h before GRF injection markedly inhibited the GH response to GRF at a peak time [integrated GH release over 30 min, 1135 +/- 271 vs. 6372 +/- 1185 ng/ml.30 min in H2O-injected controls (mean +/- SE); P less than 0.01]. In striking contrast, 5 h after rhGH administration, there was a 6-fold augmentation of GH responsiveness to GRF compared to that in H2O-injected controls at a trough time (7032 +/- 1622 vs. 1128 +/- 216 ng/ml.30 min; P less than 0.01). High GH responsiveness to GRF was preserved 7 h after rhGH injection. Passive immunization of rhGH-treated rats with SRIF antiserum reversed the rhGH-induced blunted GH response at 3 h (7985 +/- 366 vs. 1705 +/- 431 ng/ml.30 min in rhGH-treated control rats given normal sheep serum; P less than 0.01) and completely restored GH responsiveness to levels as high as those in H2O-injected controls. These results demonstrate that 1) a single sc injection of rhGH markedly attenuates GH responsiveness to GRF acutely for about 3 h, but subsequently enhances somatotroph sensitivity to the stimulatory actions of GRF; and 2) the short term blunting of GRF-induced GH release by rhGH is due at least in part to increased release of endogenous SRIF. The subsequent potentiation of GH responsiveness to GRF is probably due to a SRIF-mediated build-up of pituitary GH stores in a readily releasable pool. Such a mechanism of GH autofeedback may play a physiological role in the genesis of pulsatile GH secretion.
Similar articles
-
Time course and mechanism of growth hormone's negative feedback effect on its own spontaneous release.Endocrinology. 1992 Feb;130(2):780-8. doi: 10.1210/endo.130.2.1346379. Endocrinology. 1992. PMID: 1346379
-
Sexual dimorphism of somatostatin and growth hormone-releasing factor signaling in the control of pulsatile growth hormone secretion in the rat.Endocrinology. 1991 Jun;128(6):2858-66. doi: 10.1210/endo-128-6-2858. Endocrinology. 1991. PMID: 1674685
-
Dietary protein restriction impairs both spontaneous and growth hormone-releasing factor-stimulated growth hormone release in the rat.Endocrinology. 1993 Sep;133(3):1035-43. doi: 10.1210/endo.133.3.8103447. Endocrinology. 1993. PMID: 8103447
-
Somatostatin as a physiological regulator of pulsatile growth hormone secretion.Horm Res. 1988;29(2-3):70-4. doi: 10.1159/000180971. Horm Res. 1988. PMID: 2900199 Review.
-
[A hypothalamic hormone-somatostatin--from endocrinology to neurophysiology].Nihon Naibunpi Gakkai Zasshi. 1992 May 20;68(5):507-25. doi: 10.1507/endocrine1927.68.5_507. Nihon Naibunpi Gakkai Zasshi. 1992. PMID: 1353733 Review. Japanese.
Cited by
-
The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.J Endocrinol Invest. 2000 Mar;23(3):158-62. doi: 10.1007/BF03343699. J Endocrinol Invest. 2000. PMID: 10803472 Clinical Trial.
-
Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.Endocrine. 2001 Feb;14(1):45-62. doi: 10.1385/ENDO:14:1:045. Endocrine. 2001. PMID: 11322501 Review.
-
Effect of 6 weeks of sprint training on growth hormone responses to sprinting.Eur J Appl Physiol. 2004 Jun;92(1-2):26-32. doi: 10.1007/s00421-003-1038-5. Epub 2004 Feb 17. Eur J Appl Physiol. 2004. PMID: 14985991 Clinical Trial.
-
Regulation of basal, pulsatile, and entropic (patterned) modes of GH secretion in a putatively low-somatostatin milieu in women.Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E483-9. doi: 10.1152/ajpendo.00136.2009. Epub 2009 Jun 2. Am J Physiol Endocrinol Metab. 2009. PMID: 19491298 Free PMC article. Clinical Trial.
-
Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.J Endocrinol Invest. 1995 Nov;18(10):762-6. doi: 10.1007/BF03349808. J Endocrinol Invest. 1995. PMID: 8787952
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources